Twinbeech Capital LP Invests $1.74 Million in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Twinbeech Capital LP purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 46,797 shares of the company's stock, valued at approximately $1,738,000. Twinbeech Capital LP owned about 0.10% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in AMPH. Tower Research Capital LLC TRC lifted its stake in shares of Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares during the last quarter. Huntington National Bank increased its holdings in Amphastar Pharmaceuticals by 36.9% in the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after buying an additional 361 shares during the period. Bank of Montreal Can increased its holdings in Amphastar Pharmaceuticals by 4.6% in the 4th quarter. Bank of Montreal Can now owns 8,215 shares of the company's stock valued at $305,000 after buying an additional 361 shares during the period. TD Private Client Wealth LLC increased its holdings in Amphastar Pharmaceuticals by 22.7% in the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after buying an additional 388 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after buying an additional 493 shares during the period. Institutional investors and hedge funds own 65.09% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AMPH. Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Wells Fargo & Company decreased their price target on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $32.33.

Insider Buying and Selling

In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.02. This trade represents a 4.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 5,231 shares of company stock worth $142,752 in the last ninety days. Company insiders own 27.50% of the company's stock.

Amphastar Pharmaceuticals Trading Up 3.7%

NASDAQ:AMPH traded up $0.91 during mid-day trading on Tuesday, hitting $25.38. 112,499 shares of the company's stock were exchanged, compared to its average volume of 593,090. The company has a 50 day simple moving average of $25.13 and a 200-day simple moving average of $32.65. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $22.64 and a fifty-two week high of $53.96. The firm has a market capitalization of $1.21 billion, a P/E ratio of 8.46, a PEG ratio of 2.19 and a beta of 0.78.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.